Key result
This review summarizes the indications, risks, and up-to-date transcatheter therapeutic options for the percutaneous closure of patent foramen ovale and atrial septal defects in adult patients.
Answers are grounded in this paper and cite their sources.
This review summarizes the indications, risks, and up-to-date transcatheter therapeutic options for percutaneous closure of PFO and ASD in adult patients.
William Harvey was the first scientist to describe the heart as consisting of separate right- and left-sided circulations. Our understanding of the heart’s anatomy and physiology has grown significantly since this landmark discovery in 1628. Today, we recognise not only the importance of these separate systems, but also the specific tissue that divides them. Our growing understanding of the inter-atrial septum has allowed us to identify defects within this structure and develop effective percutaneous devices for closure of these defects in the adult patient. This article discusses the formation of a patent foramen ovale (PFO) and atrial septal defect (ASD). In addition, we describe the medical illnesses caused by these defects and summarise the indications and risks related to percutaneous closure of these defects. We also report the most up-to-date transcatheter therapeutic options for closure of these common congenital defects in the adult patient.
No takes yet. Share an insight, caveat, or question.
Slater et al. (2009) conducted a review in Patent foramen ovale (PFO) and atrial septal defect (ASD). Percutaneous closure devices was evaluated. This review summarizes the indications, risks, and up-to-date transcatheter therapeutic options for the percutaneous closure of patent foramen ovale and atrial septal defects in adult patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: